Journal article · 2026 · Open access

856. Treatment-Resistant Schizophrenia: Definitions, Current Pharmacological Strategies, and Emerging Pipeline Therapies

Myrto T. Samara

The International Journal of Neuropsychopharmacology, 29(Supplement_1), i272–i273 · Published 1 September 2026 · DOI 10.1093/ijnp/pyag040.511

Open PDFView at the publisherCite this paper

In brief

“856. Treatment-Resistant Schizophrenia: Definitions, Current Pharmacological Strategies, and Emerging Pipeline Therapies” is a 2026 journal article by Myrto T. Samara, published in The International Journal of Neuropsychopharmacology. OpenAlex counts 0 citations as of 20 November 2026. It is open access under a CC BY-NC licence: the full text is free to read at The International Journal of Neuropsychopharmacology.

Citations
0
Authors
1

Abstract

Background Antipsychotic monotherapy is the guideline-supported mainstay of treatment for schizophrenia. However, approximately 40% of patients fail to achieve an adequate response in randomized controlled trials, highlighting the significant clinical challenge of treatment-resistant schizophrenia (TRS). Despite clozapine being the gold standard for TRS, its use is often limited by concerns over its side effect profile and the need for mandatory blood monitoring. Furthermore, real-world evidence indicates that clinicians frequently prefer antipsychotic combinations over initiating clozapine. Aims & Objectives This lecture aims to provide a comprehensive overview of treatment resistance in schizophrenia. It will cover the definitions of TRS, provide an updated and detailed analysis of clozapine’s efficacy and side effect profile, examine the impact of illness duration on treatment response, and present a hierarchical ranking of pharmacological strategies through a network meta-analysis. Emerging non-pharmacological treatments will also be discussed. Method The presentation synthesizes data from multiple meta-analyses and systematic reviews, including: Clozapine Side Effect Profile: Analysis of 116 RCTs (n=8431) comparing clozapine to other antipsychotics (https://doi.org/10.1192/bjp.2025.10421) Response Rates and Illness Duration: Meta-analysis of 60 RCTs (n=11,375) examining clozapine response rates in non-TRS and TRS populations, and the nonlinear association with illness duration (https://www.nature.com/articles/s44220-026-00604-w ) Comparative Efficacy: A network meta-analysis (NMA) of 150 RCTs (n=11,375) evaluating 78 drug options, including antipsychotic monotherapies and combinations, for TRS (https://doi.org/10.1016/j.eclinm.2025.103291 ) Emerging Strategies: An unpublished systematic review including psychotherapy and neuromodulatory interventions (rTMS, ECT). Results Clozapine Safety: In 69 monotherapy RCTs, clozapine showed no significant difference from other antipsychotics in mortality or discontinuation due to adverse effects. However, it significantly increased the risk of seizures (RR 3.61, prevalence 3.1%), orthostatic hypotension/bradycardia/syncope (RR 1.66, prevalence 11%), and nearly tripled the risk of agranulocytosis (RR 2.81, prevalence 0.7%). In 47 combination RCTs, clozapine combinations were not associated with an increased risk of severe adverse effects like agranulocytosis or seizures. Response & Timing: Clozapine demonstrated a 81% response rate in non-TRS and 63% response rate in TRS patients. Response rates declined steeply in the first decade of illness (from >90% at onset to ~46% by year 10), after which they stabilized, underscoring a critical window for intervention. Comparative Efficacy: The NMA found clozapine monotherapy to be superior to several other antipsychotics. Certain clozapine combinations showed superior efficacy for overall, positive, and negative symptoms compared to clozapine monotherapy, though confidence in most estimates was low to very low. Data also suggested that some antipsychotic combinations may outperform monotherapy. Higher baseline severity was associated with higher clozapine efficacy. Discussion & Conclusions The findings reaffirm clozapine’s superior efficacy for TRS…

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Samara, M. T. (2026). 856. Treatment-Resistant Schizophrenia: Definitions, Current Pharmacological Strategies, and Emerging Pipeline Therapies. The International Journal of Neuropsychopharmacology, 29(Supplement_1), i272–i273. https://doi.org/10.1093/ijnp/pyag040.511

MLA 9

Samara, Myrto T. “856. Treatment-Resistant Schizophrenia: Definitions, Current Pharmacological Strategies, and Emerging Pipeline Therapies.” The International Journal of Neuropsychopharmacology, vol. 29, no. Supplement_1, 2026, pp. i272–i273. https://doi.org/10.1093/ijnp/pyag040.511.

Chicago

Samara, Myrto T. 2026. “856. Treatment-Resistant Schizophrenia: Definitions, Current Pharmacological Strategies, and Emerging Pipeline Therapies.” The International Journal of Neuropsychopharmacology 29 (Supplement_1): i272–i273. https://doi.org/10.1093/ijnp/pyag040.511.

Harvard

Samara, M. T. (2026) ‘856. Treatment-Resistant Schizophrenia: Definitions, Current Pharmacological Strategies, and Emerging Pipeline Therapies’, The International Journal of Neuropsychopharmacology, 29(Supplement_1), pp. i272–i273. doi:10.1093/ijnp/pyag040.511.

IEEE

M. T. Samara, “856. Treatment-Resistant Schizophrenia: Definitions, Current Pharmacological Strategies, and Emerging Pipeline Therapies,” The International Journal of Neuropsychopharmacology, vol. 29, no. Supplement_1, pp. i272–i273, 2026, doi: 10.1093/ijnp/pyag040.511.

BibTeX

@article{samara2026treatment,
  title     = {{856. Treatment-Resistant Schizophrenia: Definitions, Current Pharmacological Strategies, and Emerging Pipeline Therapies}},
  author    = {Samara, Myrto T.},
  journal   = {The International Journal of Neuropsychopharmacology},
  year      = {2026},
  volume    = {29},
  number    = {Supplement_1},
  pages     = {i272--i273},
  doi       = {10.1093/ijnp/pyag040.511},
  url       = {https://doi.org/10.1093/ijnp/pyag040.511}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment

  • treatment-resistant schizophrenia
  • clozapine
  • antipsychotic monotherapy
  • antipsychotic polypharmacy
  • clozapine side effects
  • seizures
  • orthostatic hypotension
  • disease duration

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Samara, M. T. (2026). 856. Treatment-Resistant Schizophrenia: Definitions, Current Pharmacological Strategies, and Emerging Pipeline Therapies. The International Journal of Neuropsychopharmacology, 29(Supplement_1), i272–i273. https://doi.org/10.1093/ijnp/pyag040.511

How many times has this paper been cited?

0 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at The International Journal of Neuropsychopharmacology: sign in and open the PDF from this page.

Who wrote this paper?

Myrto T. Samara.

What is the DOI of this paper?

10.1093/ijnp/pyag040.511, permanently at https://doi.org/10.1093/ijnp/pyag040.511. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.